| Description |
Eflapegrastim is a humanized IgG4 monoclonal antibody, is also a granulocyte colony-stimulating factor (G-CSF). Eflapegrastim targets to G-CSF receptor (c-Fms). Eflapegrastim stimulates proliferation and differentiation of neutrophil progenitor cells and maintains stable numbers of mature and functional neutrophils. Eflapegrastim also shortens the duration of neutropenia[1].
|
| Related Catalog |
|
| In Vitro |
Eflapegrastim 含有 IgG4 Fc 片段和短聚乙二醇连接物[1]。 Eflapegrastim (5.5-88 mM; 4 min) 与 FcRn 结合，但不与 Fcγ 受体或 C1q 结合[1]。 Eflapegrastim (0.000036-0.709 nmol/L; 54 h) 诱导骨髓细胞增殖[1]。 Eflapegrastim (10 μM; 1 h) 结合FcRn并经历FcRn介导的胞吞作用[1]。
|
| In Vivo |
Eflapegrastim (100 μg/kg; 皮下注射; 单次剂量) 降低化疗诱导的中性粒细胞减少大鼠中性粒细胞减少 (DN) 的持续时间，增加血清和骨髓中 G-CSF 的水平[1]。 Animal Model: C57BL/6NCrl mice (4-6 weeks old)[1] Dosage: (1) 9, 26, 53, and 88 µg/kg; (2) 62 µg/kg Administration: Subcutaneous injection; single dose Result: Reduced chemotherapy-induced neutropenia.
|
| References |
[1]. Barrett JA, et al. Eflapegrastim's enhancement of efficacy compared with pegfilgrastim in neutropenic rats supports potential for same-day dosing. Exp Hematol. 2020 Dec;92:51-61.
|
